vuRoyal
Massachusetts-headquartered pharmaceutical wholesaler and exporter focused on global procurement and distribution of reference listed drugs, reference standards, and saponin-derived vaccine adjuvants. Provides end-to-end clinical trial sourcing and logistics, regulatory support for importation and registration, analytical testing, and technical outreach to vaccine R&D and animal health customers.
Industries
Nr. of Employees
small (1-50)
vuRoyal
Waltham, Massachusetts, United States, North America
Products
Reference Listed Drugs (RLD) and reference standards
Legal-sourced reference listed drugs and official reference standards used for bioequivalence testing, regulatory filings, and clinical research.
Saponin-derived vaccine adjuvants (human and veterinary)
GMP-grade Quillaja saponaria-derived saponin adjuvants and veterinary saponin formulations supplied for vaccine R&D and production.
Reference Listed Drugs (RLD) and reference standards
Legal-sourced reference listed drugs and official reference standards used for bioequivalence testing, regulatory filings, and clinical research.
Saponin-derived vaccine adjuvants (human and veterinary)
GMP-grade Quillaja saponaria-derived saponin adjuvants and veterinary saponin formulations supplied for vaccine R&D and production.
Services
Sourcing and international delivery of reference listed drugs and reference standards for research and generic development.
Assistance with imported drug approval, registration filings, customs clearance, and related regulatory documentation.
Clinical trial sourcing, analytical testing coordination, over-encapsulation, clinical trial packaging, and material logistics.
Supply of Quillaja saponaria-derived saponin adjuvants for human and veterinary vaccines, plus technical and regulatory support for adjuvant use in R&D and manufacturing.
Referral coordination services that connect patients with appropriate healthcare providers and research sites to support trial enrollment (company does not serve individual patients directly).
Sourcing and international delivery of reference listed drugs and reference standards for research and generic development.
Assistance with imported drug approval, registration filings, customs clearance, and related regulatory documentation.
Clinical trial sourcing, analytical testing coordination, over-encapsulation, clinical trial packaging, and material logistics.
Supply of Quillaja saponaria-derived saponin adjuvants for human and veterinary vaccines, plus technical and regulatory support for adjuvant use in R&D and manufacturing.
Referral coordination services that connect patients with appropriate healthcare providers and research sites to support trial enrollment (company does not serve individual patients directly).
Expertise Areas
- Pharmaceutical distribution and export
- Reference listed drug procurement
- Vaccine adjuvant supply (saponin-derived)
- Clinical trial sourcing and logistics
Key Technologies
- Reverse-phase HPLC (RP-HPLC) and chromatographic purification
- GMP manufacturing practices for pharmaceutical excipients
- Cold-chain logistics and temperature-controlled transport
- Adjuvant formulation and excipient handling
News & Updates
First QS-21 Forum organized jointly with partner manufacturer in Shanghai; technical sessions on QS-21 research, quality and vaccine applications (March 20–23, 2024).
Online technical forum focused on saponin adjuvants for human and veterinary vaccines with presentations on research, clinical application, and regulatory submissions.
Article summarizing a partner manufacturer's attainment of EXCiPACT certification for GMP/GDP compliance at its pharmaceutical excipient production facility (April 24, 2025).
Overview of Quillaja saponaria-derived saponin fractions and their purification by reverse-phase chromatography; summary of clinical and preclinical applications.
The company's agency application for registration of a Quillaja saponaria-derived excipient (acting as exclusive agent in China) entered Public Notice Phase I after review by the national drug evaluation authority.
First QS-21 Forum organized jointly with partner manufacturer in Shanghai; technical sessions on QS-21 research, quality and vaccine applications (March 20–23, 2024).
Online technical forum focused on saponin adjuvants for human and veterinary vaccines with presentations on research, clinical application, and regulatory submissions.
Article summarizing a partner manufacturer's attainment of EXCiPACT certification for GMP/GDP compliance at its pharmaceutical excipient production facility (April 24, 2025).
Overview of Quillaja saponaria-derived saponin fractions and their purification by reverse-phase chromatography; summary of clinical and preclinical applications.
The company's agency application for registration of a Quillaja saponaria-derived excipient (acting as exclusive agent in China) entered Public Notice Phase I after review by the national drug evaluation authority.